BTLA nucleic acids

Details BTLA nucleic acids BTLA nucleic acids

2007-12-04

2007-12-04

Gambel, Phillip (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C435S320100, C435S252300, C435S455000, C435S069100

Reexamination Certificate

active

10600997

ABSTRACT:
The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7xas interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7xfor therapeutic, diagnostic and research purposes are also provided.

REFERENCES:
patent: 7153950 (2006-12-01), Clark et al.
patent: 2004/0091884 (2004-05-01), Clark et al.
patent: WO 99/40100 (1999-08-01), None
patent: WO 02/02624 (2002-01-01), None
patent: WO 02/06317 (2002-01-01), None
patent: WO 02/10187 (2002-02-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/16581 (2002-02-01), None
patent: WO 02/072794 (2002-09-01), None
patent: WO 2004/000221 (2003-12-01), None
Attwood T., Science 2000; 290:471-473.
Peach et al., J. Exp. Med., 1994, 180: 2049-2058.
Watanabe et al., NCBI Accession No. AY293286; May 8, 2003.
Watanabe et al., Nature Immunol., 2003, 4: 670-679.
pGEM-T Technical Manual, Promega, 2005, p. 2.
Abbas, A.K., et al., “T-cell stimulation: an abundance of B7s,”Nat. Med. 5(12):1345-1346 (Dec. 1999).
Anderson, D., et al., “Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population,”Nat. Med. 6(2):211-214 (Feb. 2000).
Arceci, R., “The potential for antitumor vaccination in acute myelogenous leukemia,”J. Mol. Med. 76:80-93 (1998).
Bodey, B., et al., “Failure of cancer vaccines: the significant limitations of this approach to immunotherapy,”Anticancer Res. 20(4):2665-2676 (Jul.-Aug. 2000).
Brodie, D., et al., “LICOS, a primordial costimulatory ligand,”Curr. Biol. 10(6):333-336 (Mar. 2000).
Carreno, B.M., et al., “B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune response,”Annu. Rev. Immunol. 20:29-53 (2002).
Chambers, C., et al., “CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy,”Annu. Rev. Immunol. 19:565-594 (2001).
Chambers, C., et al., “Thymocyte development is normal in CTLA-4-deficient mice,”Proc. Natl. Acad. Sci. USA94(17):9296-9301 (Aug. 1997).
Chapoval, A.I., et al., “B7-H3: a costimulatory molecue for T cell activation and IFN-γ production,”Nat. Immunol. 2(3):269-274 (Mar. 2001).
Christadoss, P., et al., “Animal models of Myasthenia gravis,”Clin. Immunol. 94(2):75-87 (Feb. 2000).
Coyle, A.J., et al., “The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T-cell function,”Nat. Immunol. 2(3):203-209 (Mar. 2001).
Damle, N., et al., “Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7,”J. Immunol. 152:2686-2697 (1994).
Dong, H., et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,”Nat. Med. 5(12):1365-1369 (Dec. 1999).
Dudley, M.E., et al., “Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes,”Science268(5594):850-854 (Oct. 2002).
Egen, J.G., et al., “CTLA-4: new insights into its biological function and use in tumor,”Nat. Immunol. 3(7):611-618 (Jul. 2002).
Freeman, G.J., et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activity,”J. Exp. Med. 192(7):1027-1034 (Oct. 2000).
Gao, P., et al., “Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumors even in combination with interleukin-12 treatment: the importance of inducing intratumoral T-cell migration,”J. Immunother. 23(6):643-653 (2000).
Gribben, G., et al., “Alloantigen and concomitant CTLA4 signaling induces clonal deletion of alloreative T cells: a novel method to prevent GVHD,”Blood84(10):397a (1994).
Heslop, H., “Cytokine gene transfer in the therapy of malignancy,”Baillière Clin. Haematol. 7(1):135-151 (Mar. 1994).
Kearney, E., et al., “Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4,”J. Immunol. 155(3):1032-1036 (Aug. 1995).
Krummel, M., et al., “Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo,”J. Exp. Med. 182(2):459-465 (Aug. 1996).
Latchman, Y., et al., “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,”Nat. Immunol. 2(3):261-268 (Mar. 2001).
Leach, D., et al., “Enhancement of antitumor immunity by CTLA-4 blockade,”Science271(5256):1734-1739 (Mar. 1996).
Lee, K.-H., et al., “Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression,”J. Immunol. 163(11):6292-6300 (Dec. 1999).
Lewis, G., et al., “Growth regulation of human breast and ovarian tumor cells by heregulin: evidence of the requirement of ErbB2 as a critical component in mediating heregulin responsiveness,”Cancer Res. 56:1457-1465 (Mar. 1996).
Liang, P., et al., “The right place at the right time: novel B7 family members regulate effector T-cell responses,”Curr. Opin. Immunol. 14(3):384-390 (Jun. 2002).
Ling, V., et al., “Cutting Edge: Identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor,”J. Immunol. 164(4):1653-1657 (Feb. 2000).
Nishimura, H., et al., “PD-1: an inhibitory immunoreceptor involved in peripheral tolerance,”Trends Biotechnol. 22(5):265-268 (May 2001).
Pardoll, D.M., et al., “Tumor reactive T cells get a boost,”Nat. Biotechnol. 20(12):1207-1208 (Dec. 2002).
Sotomayor, E., et al., “In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent to induction of tumor antigen-specific tolerance,”Proc. Natl. Acad. Sci. USA96(20):11476-11481 (Sep. 1999).
Sun, M., et al., “Characterization of mouse and human B7-H3 genes,”J. Immunol. 168(12):6294-6297 (Jun. 2002).
Sussman, J., et al., “Activation of T lymphocytes for the adoptive immunotherapy of cancer,”Ann. Surg. Oncol. 1(4):296-306 (Jul. 1994).
Swallow, M.M., et al., “B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFα,”Immunity11(4):423-432 (Oct. 1999).
Timmerman, J., et al., “Dendritic cell vaccines for cancer immunotherapy,”Annu. Rev. Med. 50:507-529 (1999).
Triozzi, P., et al., “Clinical and immunologic effects of a synthetic β-human chorionic gonadotropin vaccine,”Int. J. Oncol. 5:1447-1453 (1994).
Tseng, S.Y., et al., “B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells,”J. Exp. Med. 193(7):839-846 (Apr. 2001).
Wallack, M., et al., “Active specific immunotherapy with vaccinia melanoma oncolysate,”Immunity1(5):405-413 (Aug. 1994).
Wang, S., et al., “Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS,”Blood96(8):2808-2813 (Oct. 2000).
Yang, Y., et al., “Enhanced induction of antitumor T-cell by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages,”Cancer Res. 57:4036-4041 (Sep. 1997).
Yoshinaga, S.K., et al., “T-cell co-stimulation through B7RP-1 and ICOS,”Nature402(6763):827-832 (Dec. 1999).
Zaks, T., et al., “Immunization with a peptide epitope (p369-377) from HER-2
eu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2
eu+ tumors

Affiliated with

Also associated with

Rating

BTLA nucleic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BTLA nucleic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BTLA nucleic acids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3874373